disrupting.healthcare

HealthTech and Digital Health. disrupting.healhcare is a website that follows the progress of tech and digital innovation in healthcare.

[disrupting.healthcare @DisruptingH]

Quiet week in life sciences. Loud signal.

GSK: oral carbapenem.
Roche: subcut lymphoma regimen for community care.
Germany: drug pricing is trade policy.
Novo: oral GLP-1 race.
The molecule earns approval.
The delivery model earns the market.

https://t.co/ao3RCvglvc

[disrupting.healthcare @DisruptingH]

New AI-guided MDR platform from HTH Copenhagen.
Most interesting founder insight: startups didn’t mainly get stuck on regulation. They got stuck defining intended use, clinical claims and target users.

The bottleneck was upstream of MDR.
https://t.co/QFbDjXRzsW

[disrupting.healthcare @DisruptingH]

The signal this week: AI, obesity, supply resilience and device regulation are becoming the same leadership problem — governance that can actually operate.

Europe Life Sciences Weekly Signal #37: When the Operating Layer Becomes the Strategy - https://t.co/5BOgjTOH9q

[disrupting.healthcare @DisruptingH]

Europe life sciences this week: Roche bought pathology AI, UCB bought into immune reset, Angelini bought US rare-disease reach.

Capability is no longer the moat. Integration is.

https://t.co/5f2GL9vNe5

[disrupting.healthcare @DisruptingH]

This week’s Europe life-sciences signal:
The boring stuff is becoming strategic.

AstraZeneca UK, Chiesi/KalVista, Novartis, EMA’s breakthrough-device pilot, EUDAMED, AI funding all point to one thing:

Access plumbing is now commercial strategy.
https://t.co/5BOgjTOH9q

[disrupting.healthcare @DisruptingH]

Platform M&A, EMA evidence pressure, NICE thresholds, EUDAMED readiness and EU health AI funding all pointed to one thing this week:

In European life sciences, strategy is becoming operating reality.

Weekly Signal #34 is live:
https://t.co/6BQGh7exIZ

[disrupting.healthcare @DisruptingH]

Europe life sciences this week: less AI theatre, more hard reality. https://t.co/E8TwtWLkn1

Capital is backing platforms. Regulators want readiness. Reimbursement is getting tighter.

Loose sequencing is over.

#LifeSciences #Pharma #MedTech

[disrupting.healthcare @DisruptingH]

European MedTech is not just about innovation right now. It is about who controls the operating layer: data, workflow, diagnostics, resilience.
New weekly brief on https://t.co/XEkoahojPl

[disrupting.healthcare @DisruptingH]

Agentic AI doesn't make omnichannel smarter.
It exposes every structural flaw that was already there.
What actually has to change in your pharma commercial operating model before you deploy 👇
https://t.co/kqWEbahjMT

[disrupting.healthcare @DisruptingH]

AI in healthcare is moving from pilots to operations.

This week in Europe MedTech:
• hospital AI
• clinical trial infra
• Abbott deal
• Stryker cyber hit
https://t.co/UFiWHWLbhl
#MedTech #DigitalHealth

[disrupting.healthcare @DisruptingH]

Europe’s healthtech market is shifting fast.

From unicorn platforms (Doctolib, Alan) to AI innovators (Owkin) and disruptors like Neko Health — here’s who actually matters in 2026 👇
https://t.co/sv2kWk7FRM
#HealthTech #DigitalHealth #MedTech #AI #Startups

[disrupting.healthcare @DisruptingH]

Most medtech teams don’t have a channel problem. They have an operating model problem.
In Europe, omnichannel breaks when evidence, field teams, local market realities, and digital execution are separated.

New on @DisruptingH:
https://t.co/iDqohEcO4N

[disrupting.healthcare @DisruptingH]

New: Europe MedTech News

This week’s signal: deployment readiness is winning over AI theatre.

Waiv, Vitestro, MiniMed, EIT Health, and EU AI policy:

https://t.co/n47MKe34vj

#MedTech #DigitalHealth #Europe

[disrupting.healthcare @DisruptingH]

Europe medtech this week: Xsensio funding, FARAPULSE CE mark expansion, UK NICE policy shifts, plus updates from Cellbox, Noxon, BD, and Intuitive.

https://t.co/NxufVvV7EN

#MedTech #DigitalHealth #HealthTech #Europe

[disrupting.healthcare @DisruptingH]

This week in Europe MedTech: less friction, more funding. 🇪🇺 Brief #26 is out: 🚀 Axelera AI (€211M edge AI) 🚀 Oska Health (€11M chronic care) 🚀 Quantum Surgical (robotics M&A) 🚀 EHDS data "plumbing" upgrades
Read here: https://t.co/LOj7S2yA20
#HealthTech #MedTech

[disrupting.healthcare @DisruptingH]

Regulatory friction? 📉 Funding for compliance? 📈
🇬🇧 UK MHRA launches a massive consultation on indefinite CE mark recognition.
🤖 Workflow and regulatory AI grabs the cash ($20M for Flinn, €7.6M for Xyall).
https://t.co/WuSIR4eiU4
#MedTech #DigitalHealth #HealthTech

[disrupting.healthcare @DisruptingH]

Regulatory Win:
• @Senseonics gets CE Mark for Eversense 365—the world’s first 1-year implantable CGM.

The barriers to entry are shifting.
https://t.co/Ir2fde2xwD

[disrupting.healthcare @DisruptingH]

Money Flows: • @SamanTreeMed secures €20M from EIB for real-time surgical imaging 🔬 • Evaro raises €23.1M Series A to scale NHS-licensed embedded care with partners like @clue • MedVasc lands €2.2M for pain-free vascular care.
https://t.co/Ir2fde35mb

[disrupting.healthcare @DisruptingH]

Is Rule 11 finally dying? 💀
The EU Commission’s proposal could move many Imaging AI tools from Class IIa back to Class I saving startups years and €100ks in fees.

Read why 2026 is the "Great Reset" for EU SaMD: https://t.co/5BOgjTOH9q

#ImagingAI #MDR #AIAct #HealthTech

[disrupting.healthcare @DisruptingH]

Europe MedTech Weekly Brief #22 is live!

The "Great Regulatory Rationalization" begins
From radical MDR simplifications to €23M Series A for digital pharmacy, the ecosystem is trading complexity for clarity.

Read the full brief: https://t.co/Ir2fde2xwD
#MedTech #DigitalHealth